Navigation Links
Marken Appoints New Directors To Board
Date:3/5/2013

RESEARCH TRIANGLE PARK, N.C., March 5, 2013 /PRNewswire/ -- Marken today announced that it has appointed two independent directors to its Board as a result of Marken's recent restructuring completed on December 21, 2012.  The appointment of Timothy C. Tyson and Michael O'Donnell is the next step in Marken's strategy to focus on serving the global life sciences industry.

(Logo:  http://photos.prnewswire.com/prnh/20110930/NY78064LOGO)

Tim Tyson is a veteran leader in the global pharmaceutical market place.  He currently serves as Chairman of the Board of Aptuit LLC, a global pharmaceutical services company based in the US.  He was CEO and President of Valeant Pharmaceuticals Inc. from 2003-2008.  Prior to that, Mr. Tyson held various leadership roles including as President, Global Manufacturing & Supply at GlaxoSmithKline (GSK).  During his 14 years at GSK, he led the Glaxo Dermatology and Cerenex Divisions, the US Marketing Division, and the US Sales Divisions where he launched 32 products, eight of which exceeded $1billion in global sales.  Mr. Tyson is an engineering graduate of the US Military Academy at West Point, and holds a masters degree in public administration from Jackson State University. He has held key positions on the PhRMA Board and the International Society of Professional Engineers (ISPE).

Michael O'Donnell currently serves as Chairman of Verna, a company specializing in infectious control products, and as non-executive Director of Helical Bar plc. a property development firm.  He has served as an independent Director on the Boards of seven companies since 2008 and also acted as a consultant to one of Marken's clients.  Prior to 2008, Mr. O'Donnell was a Managing Director of LGV Capital, a private equity firm, where he worked for more than a decade. He started his career at Morgan Grenfell where he worked for five years after graduating from University College, Dublin with a Bachelor of Commerce degree. 

"We are delighted to welcome Tim and Michael to Marken's Board of Directors," said Wes Wheeler , Marken's Chief Executive Officer.  "These two independent Directors will certainly provide us with an appropriate balance of deep industry and financial experience.  They also bring excellent contacts from the pharmaceutical industry and the UK financial markets, respectively, which will allow us to continue our expansion in the life sciences supply chain market." 

About Marken
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.


'/>"/>
SOURCE Marken
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
2. Marken Opens Branch Office In Seoul, South Korea
3. Marken Announces Global Advisory Board
4. Marken Launches New Global Regulatory Consultation Services
5. Marken Enhances Branch Operations
6. Marken Expands Regulatory And Technical Excellence In Logistics
7. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
8. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
9. Nephros Appoints John C. Houghton as President and Chief Executive Officer
10. Elsevier Appoints New President of Elsevier CPM Resource Center
11. GenWay Biotech Appoints New Vice President of Custom/OEM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
Breaking Medicine News(10 mins):